Printer Friendly

GENESYS PHARMA INC. ANNOUNCES SCIENTIFIC ADVISORY MEETING

 VANCOUVER, British Columbia, March 31 /PRNewswire/ -- Genesys Pharma Inc.'s (Vancouver: GPI) scientific advisers' meeting on April 19, 1993 will review the company's progress of its AIDS antisense compound "DNS-BP2R," which is being tested at the Manitoba Institute of Cell Biology under the direction of Dr. Jim Wright and at the McGill AIDS Centre of Montreal under the direction of Dr. Mark A. Wainberg. Information for the submission of an IND and patent application information to government regulatory bodies has been prepared and the meeting will determine the nature of its filing. Testing at Wright's laboratory, Manitoba Institute of Cell Biology has shown that GPI's antisense drug does block the production of proteins essential for the replication of the AIDS virus. The drug is now being tested with live AIDS virus at Wainberg's laboratory; Lady Davis Research Institute, McGill University, Montreal. Preliminary results are very encouraging and the process of patenting and clinical testing is beginning. Further details will be released after the scientific advisory meeting.
 -0- 3/31/93
 /CONTACT: Peter de Visser, director of Genesys Pharma, 604-687-2151/
 (GPI.)


CO: Genesys Pharma Inc. ST: British Columbia IN: MTC SU:

KJ -- LA033 -- 1778 03/31/93 19:38 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1993
Words:199
Previous Article:EDMARK FILES REGISTRATION STATEMENT
Next Article:THE PRESLEY COMPANIES ANNOUNCES BANK AGREEMENTS
Topics:


Related Articles
UroGenesys Names Aya Jakobovits, Ph.D. Vice President of Research and Chief Scientific Officer.
Cell Genesys and Mitotix Expand Collaboration to Include Cancer Gene Therapy.
The Quigley Corporation Convenes Scientific Advisory Board for Quigley Pharma.
Quigley Pharma's Scientific Advisory Board is Encouraged by Research Results; Strongly Supports Next Stage of Development.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters